ADARx Pharmaceuticals has initiated the process to list on the Nasdaq Global Market, registering a proposed initial public offering under the ticker symbol ADRX, the company said in a press release. The filing stops short of providing specifics on when the sale would occur or how large the offering might be; ADARx did not disclose timing or size.
The company characterizes itself as a late-clinical stage biotechnology firm concentrating on siRNA therapeutics. ADARx indicated its development portfolio comprises three programs that are at the clinical stage and two programs in advanced preclinical development, covering multiple disease targets.
ADARx described the mechanism of its therapeutic approach, noting that siRNA treatments work at the genetic level by targeting mRNA or RNA in affected cells and do so without making permanent changes to a patients DNA.
Several major investment banks have been retained to underwrite the offering. Named in the filing are J.P. Morgan, Morgan Stanley, TD Cowen, UBS Investment Bank, and LifeSci Capital as the underwriters for the proposed transaction.
Context and implications
The filing places ADARx among late-clinical stage biotechs that are pursuing public capital to advance development activities. The companys mix of clinical-stage and advanced preclinical programs indicates that its commercial trajectory will depend on the progress of those programs, while the lack of disclosed timing or offering size leaves the market without immediate detail on the potential capital raise or timeline for funds to become available.
Deal structure and market participants
ADARx has engaged a group of established investment banks to manage the IPO process. The listed underwriters - J.P. Morgan, Morgan Stanley, TD Cowen, UBS Investment Bank, and LifeSci Capital - will handle syndication and investor outreach should the company move forward with an offering.
What is not disclosed
The companys filing does not include the size of the proposed offering or any indication of the timing for a market debut. Those key details remain to be announced.